ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 159 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q2 2018. The put-call ratio across all filers is 1.18 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $1,999,000 | -7.8% | 31,483 | +0.7% | 0.01% | -16.7% |
| Q1 2019 | $2,169,000 | +65.1% | 31,268 | +3.5% | 0.01% | +50.0% |
| Q4 2018 | $1,314,000 | -46.2% | 30,221 | -5.5% | 0.00% | -33.3% |
| Q3 2018 | $2,443,000 | -1.8% | 31,996 | -1.2% | 0.01% | -14.3% |
| Q2 2018 | $2,489,000 | +47.7% | 32,381 | -2.0% | 0.01% | +40.0% |
| Q1 2018 | $1,685,000 | +35.8% | 33,052 | +23.5% | 0.01% | +66.7% |
| Q4 2017 | $1,241,000 | -8.8% | 26,767 | +4.8% | 0.00% | -25.0% |
| Q3 2017 | $1,360,000 | -12.1% | 25,535 | +2.5% | 0.00% | -20.0% |
| Q2 2017 | $1,547,000 | -4.2% | 24,910 | +4.6% | 0.01% | 0.0% |
| Q1 2017 | $1,614,000 | -35.0% | 23,810 | -32.6% | 0.01% | -37.5% |
| Q4 2016 | $2,483,000 | +1.7% | 35,320 | +2.6% | 0.01% | 0.0% |
| Q3 2016 | $2,442,000 | +44.7% | 34,430 | -0.2% | 0.01% | +33.3% |
| Q2 2016 | $1,688,000 | -24.8% | 34,510 | -2.7% | 0.01% | -25.0% |
| Q1 2016 | $2,246,000 | – | 35,480 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 38,100 | $2,928,000 | 1.67% |
| Opaleye Management Inc. | 80,000 | $6,149,000 | 1.59% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 410,000 | $31,517,000 | 1.06% |
| Opus Point Partners Management, LLC | 6,311 | $485,000 | 1.05% |
| SECTOR GAMMA AS | 68,015 | $5,228,000 | 0.87% |
| Capital Impact Advisors, LLC | 27,074 | $2,061,000 | 0.76% |
| FORTALEZA ASSET MANAGEMENT INC/ | 1,130 | $87,000 | 0.71% |
| CAPITAL INTERNATIONAL LTD /CA/ | 46,957 | $3,610,000 | 0.63% |
| Virtus ETF Advisers LLC | 8,794 | $676,000 | 0.60% |
| Rock Springs Capital Management LP | 200,000 | $15,374,000 | 0.59% |